CAMBRIDGE--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that data from four abstracts from the Company’s clinical development program in support of tazemetostat for use in non-Hodgkin lymphoma (NHL) will be presented during the American Society of Hematology Meeting on Lymphoma Biology, to be held in Colorado Springs, CO, from June 18 to June 21, 2016.
Tazemetostat is a first-in-class EZH2 inhibitor currently in phase 2 studies in advanced B-cell non-Hodgkin lymphoma (NHL) and certain genetically defined solid tumors. Among the data to be presented is the first interim report from the Company’s ongoing phase 2 study in patients with NHL.
Planned Presentations:
Oral Presentation: EZH2 as a target for non-Hodgkin lymphoma and
beyond: tazemetostat experience; from bench to bedside and back to the
bench
Speaker: Vincent Ribrag, MD, Institut Gustave-Roussy,
Paris, France
Session Title: Exciting New
Mechanisms-Targeted Therapies and Clinical Trials
Date: June
21, 2016
Time: 10:20 a.m. – 10:50 a.m. Mountain Time
Poster: Tazemetostat treatment drives wild-type and mutant EZH2
DLBCL cell lines to a cell fate decision between apoptosis or
differentiation (Poster #39)
Author: Michael Thomenius,
Ph.D., Epizyme
Date: June 19, 2016
Time: 3:45
p.m. – 5:15 p.m. Mountain Time
Poster: Initial report from a phase 2 multi-center study of
tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2
(EZH2), in patients with relapsed or refractory B-cell non-Hodgkin
lymphoma (Poster #98)
Author: Franck Morschhauser, MD, PhD,
Centre Hospitalier Régional Universitaire de Lille, Lille, France
Date:
June 20, 2016
Time: 3:45 p.m. – 5:15 p.m. Mountain
Time
Poster: Chromatin flow cytometry based assessment of H3K27me3
pharmacodynamics in blood from diffuse large B-cell lymphoma (DLBCL) and
follicular lymphoma (FL) patients following exposure to the EZH2
inhibitor tazemetostat reveals disparate response profiles in specific
PMBC subpopulations (Poster #38)
Author: Christopher
Plescia, Epizyme
Date: June 20, 2016
Time: 3:45
p.m. – 5:15 p.m. Mountain Time
About the Tazemetostat Clinical Trial Program
Tazemetostat,
a first-in-class EZH2 inhibitor, is currently being studied in ongoing
phase 2 programs in both non-Hodgkin lymphoma and certain genetically
defined solid tumors, including INI1-negative and SMARCA4-negative
tumors and synovial sarcoma.
The Company has announced plans to initiate additional clinical evaluations of tazemetostat in 2016, including both a combination study with R-CHOP and a combination study with an immune checkpoint inhibitor in patients with NHL, as well as a monotherapy study in patients with mesothelioma.
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage
biopharmaceutical company creating novel epigenetic therapeutics for
cancer patients. Epizyme has built a proprietary product platform that
the Company uses to create small molecule inhibitors of a 96-member
class of enzymes known as histone methyltransferases, or HMTs. HMTs are
part of the system of gene regulation, referred to as epigenetics, that
controls gene expression. Genetic alterations can result in changes to
the activity of HMTs, making them oncogenic (cancer-causing). By
focusing on the genetic drivers of cancers, Epizyme's targeted science
seeks to match the right medicines with the right patients.
For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.
Cautionary Note on Forward-Looking Statements
Any statements
in this press release about future expectations, plans and prospects for
Epizyme, Inc. and other statements containing the words "anticipate,"
"believe," "estimate," "expect," "intend," "may," "plans," "predict,"
"project," "target," "potential," "will," "would," "could," "should,"
"continue," and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: uncertainties inherent in the initiation
of future clinical studies or expansion of ongoing clinical studies,
availability and timing of data from ongoing clinical studies, whether
preclinical data and results from clinical trials will be predictive of
the results of future trials, whether the Company’s collaborations will
be successful, expectations for regulatory approvals, availability of
funding sufficient for the Company’s foreseeable and unforeseeable
operating expenses and capital expenditure requirements, other matters
that could affect the availability or commercial potential of the
Company’s therapeutic candidates or companion diagnostics and other
factors discussed in the "Risk Factors" section of our Form 10-Q most
recently filed with the SEC, and in our other filings from time to time
with the SEC. In addition, the forward-looking statements included in
this press release represent the Company's views as of the date hereof.
The Company anticipates that subsequent events and developments will
cause the Company's views to change. However, while the Company may
elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the date
hereof.